We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Blood Tests Differentiate Myocardial Injury from Infarction

By LabMedica International staff writers
Posted on 03 Oct 2018
Myocardial infarction represents the death of myocardial cells and is characterized by acute myocardial ischemia. More...
Nonischemic myocardial injury by comparison is often associated with other conditions such as renal failure or heart conditions like myocarditis.

A new definition of acute myocardial infarction (MI) that separates it from myocardial injury presents an opportunity for laboratories to fully leverage high-sensitivity cardiac troponin (hs-cTn) assays and provide better guidance to physicians on interpreting cTn results.

An international team of experts led by a specialist at the Aarhus University Hospital (Aarhus, Denmark) have issued the Fourth Universal Definition of MI and also commented on multiple approaches that use early data to predict who will have an acute MI and who will rule out. The document lists these various screening and triage approaches for rapid rule in and rule out, listing some of the pros and cons of each approach.

Biomarkers cTn I and T help define who has acute MI. Myocardial injury reflects an elevated cTn value above the 99th percentile upper reference limit. When cTn values rise and fall due to myocardial ischemia with at least one value exceeding the 99th percentile, then the definition changes to acute MI. The advent of hs-cTn assays underscores the need to create this differentiation between heart attack and injury.

Clinical laboratory scientists in the wake of this new definition could take several measures to help physicians appropriately use and interpret hs-cTn results. Consistent use of the 99th percentile protocol is one such approach. Laboratories sometimes decide that the 99th percentile is something else and use their own cutoffs. This undermines the guidance the Universal Fourth Definition is trying to achieve.

Laboratories also need to work on turnaround time to prevent emergency department overcrowding as when the emergency department is overloaded, all patients suffer. Allan Jaffe, MD, a cardiologist and guideline co-author, said, “It’s hard to suggest approaches to evaluate changing patterns or results or when to consider other possibilities when these are set up as if one is using the assays properly and someone else is using different cutoffs. Then it doesn’t work well. It’s important that labs start to come together and stop deciding that the 99th percentile is something else.” The study was published on August 28, 2018, in the European Heart Journal.

Related Links:
Aarhus University Hospital


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.